Connect your AI

Arvinas ARVN Contract Liabilities

Contract Liabilities at other companies

Nurix Therapeutics, Inc.NRIX

$7.59M-68.6%

Kymera TherapeuticsKYMR

$0—

Arcus BiosciencesRCUS

$79M-72.9%

Other financials

Income statement

Revenue$15.6M-91.7%

Operating income-$63.8M-189%

Net income-$57.6M-169%

EPS (diluted)-$0.90-179%

Balance sheet

Cash & equivalents$87.3M+7.8%

Total debt$8.6M-19.6%

Total equity$386.8M-41.4%

Total assets$647.5M-35.3%

Cash flow

Operating cash flow-$69.2M+22.2%

CapEx$1.3M+225%

Free cash flow-$70.5M+21.1%

Valuation

Market cap$518.11M-4.6%

Enterprise value$439.41M-7.1%

P/S5.8×+4.5×

Profitability

Operating margin-283.8%-310pp

Net margin-247.5%-260pp

FCF margin-287.4%—

Returns & leverage

Return on equity-42.3%-53.5pp

Debt / equity0×0.0×

Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arvinas's contract liabilities?: Arvinas (ARVN) reported contract liabilities of $138.2M in Q1 2026.
How has Arvinas's contract liabilities changed year-over-year?: Arvinas's contract liabilities increased by 16.7% year-over-year, from $118.4M to $138.2M.
What is the long-term trend for Arvinas's contract liabilities?: Over 5 years (2020 to 2025), Arvinas's contract liabilities has grown at a 42.4% compound annual growth rate (CAGR), from $22.9M to $134.3M.
What does contract liabilities mean?: Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.